Association of acylated ghrelin profiles with chronic inflammatory markers in overweight and obese postmenopausal women: A MONET study

European Journal of Endocrinology

Volumn 157, Issue 4, 2007, Pages 419-426

  St Pierre, David H ^a   Bastard, Jean Philippe ^b   Coderre, Lise ^a   Brochu, Martin ^c   Karelis, Antony D ^d   Lavoie, Marie Ève ^a   Malita, Florin ^a   Fontaine, Jonathan ^a   Mignault, Diane ^a   Cianflone, Katherine ^e   Imbeault, Pascal ^f   Doucet, Éric ^f   Rabasa Lhoret, Rémi ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GHRELIN; GLUCOSE; INSULIN; LIPID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ACYLATION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; OBESITY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; TIME;

ACETYLATION; ACETYLTRANSFERASES; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; GHRELIN; GLUCOSE CLAMP TECHNIQUE; HUMANS; INFLAMMATION MEDIATORS; MIDDLE AGED; OBESITY; OVERWEIGHT; POSTMENOPAUSE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 35548956022     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0038     Document Type: Article

References (55)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H & Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 656-660.
2. Kojima M & Kangawa K. Ghrelin: structure and function. Physiological Reviews 2005 85 495-522.
3. Williams DL & Cummings DE. Regulation of ghrelin in physiologic and pathophysiologic states. Journal of Nutrition 2005 135 1320-1325.
4. Popovic V & Duntas LH. Leptin TRH and ghrelin: influence on energy homeostasis at rest and during exercise. Hormone Metabolic Research 2005 37 533-537.
5. St-Pierre DH, Wang L & Tache Y. Ghrelin: a novel player in the gut-brain regulation of growth hormone and energy balance. News in Physiological Sciences 2003 18 242-246.
6. Ghigo E, Broglio F, Arvat E, Maccario M, Papotti M & Muccioli G. Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clinical Endocrinology 2005 62 1-17.
7. Patterson M, Murphy KG, le Roux CW, Ghatei MA & Bloom SR. Characterization of ghrelin-like immunoreactivity in human plasma. Journal of Clinical Endocrinology and Metabolism 2005 90 2205-2211.
8. St-Pierre DH, Karelis AD, Coderre L, Malita F, Fontaine J, Mignault D, Brochu M, Bastard JP, Cianflone K, Doucet E, Imbeault P & Rabasa-Lhoret R. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2007 92 264-269.
9. le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA & Bloom SR. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. Journal of Clinical Endocrinology and Metabolism 2005 90 1068-1071.
10. Anderwald C, Brabant G, Bernroider E, Horn R, Brehm A, Waldhausl W & Roden M. Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 2003 52 1792-1798.
11. Paik KH, Choe YH, Park WH, Oh YJ, Kim AH, Chu SH, Kim SW, Kwon EK, Han SJ, Shon WY & Jin DK. Suppression of acylated ghrelin during oral glucose tolerance test is correlated with whole-body insulin sensitivity in children with Prader-Willi syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 1876-1881.
12. Gauna C, Delhanty PJ, Holland LJ, Janssen JA, Broglio F, Ross RJ, Ghigo E & van der Lely AJ. Ghrelin stimulates, hereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. Journal of Clinical Endocrinology and Metabolism 2005 90 1055-1060.
13. Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Holland LJ, Broglio F, Ghigo E & van der Lely AJ. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 2004 89 5035-5042.
14. Behre CJ, Fagerberg B, Hulten LM & Hulthe J. The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. Metabolism 2005 54 439-444.
15. Corica F, Allegra A, Corsonello A, Buemi M, Calapai G, Ruello A, Nicita Mauro V & Ceruso D. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects. International Journal of Obesity and Related Metabolic Disorders 1999 23 355-360.
16. Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J & Bastard JP. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003 17 1503-1511.
17. Dixit VD & Taub DD. Ghrelin and immunity: a young player in an old field. Experimental Gerontology 2005 40 900-910.
18. Li WG, Gavrila D, Liu X, Wang L, Gurmlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C & Weintraub NL. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 2004 109 2221-2226.
19. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW, Jr & Taub DD. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. Journal of Clinical Investigation 2004 114 57-66.
20. Luo FM, Liu XJ, Li SQ, Wang ZL, Liu CT & Yuan YM. Circulating ghrelln in patients with chronic obstructive pulmonary disease. Nutrition 2005 21 793-798.
21. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C & Kangawa K. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001 104 2034-2038.
22. DeFronzo RA, Tobin JD & Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979 237 E214-E223.
23. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
25. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA & Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? Journal of Clinical Endocrinology and Metabolism 2001 86 1020-1025.
26. Charuruks N, Laohajinda B, Rujiwanitgun S & Chaiworaporn M. Reference value for C-reactive protein and its distribution pattern in Thai adults. Circulation Journal 2005 69 339-344.
27. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF & Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clinical Chemistry 2001 47 426-430.
28. Johansson A, Ahren B, Forsberg H & Olsson T. Testosterone and diurnal rhythmicity of leptin, TNF-α and TNF-II receptor in insulin-resistant myotonic dystrophy patients. International Journal of Obesity and Related Metabolic Disorders 2002 26 1386-1392.
29. Jellema A, Plat J & Mensink RP. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. European Journal of Clinical Investigation 2004 34 766-773.
30. Twickler TB, Dalllnga-Thie GM, Visseren FL, de Vries WR, Erkelens DW & Koppeschaar HP. Induction of postprandial inflammatory response in adult onset growth hormone deficiency is related to plasma remnant-like particle-cholesterol concentration. Journal of Clinical Endocrinology and Metabolism 2003 88 1228-1233.
31. Nappo E Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R & Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. Journal of the American College of Cardiology 2002 39 1145-1150.
32. Ikezaki A, Hosoda H, Ito K, Iwama S, Miura N, Matsuoka H, Kondo C, Kojima M, Kangawa K & Sugihara S. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 2002 51 3408-3411.
33. Mohlig M, Spranger J, Otto B, Ristow M, Tschop M & Pfeiffer AF. Euglycemic hyperinsulinemia, but not lipid infusion, decreases circulating ghrelin levels in humans. Journal of Endocrinological Investigation 2002 25 RC36-RC38.
34. Halle M, Berg A, Northoff H & Keul J. Importance of TNF-α and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exercise Immunology Review 1998 4 77-94.
35. Winkler G, Lakatos P, Salamon F, Nagy Z, Speer G, Kovacs M, Harmos G, Dworak O & Cseh K. Elevated serum TNF-α level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabetic Medicine 1999 16 207-211.
36. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M & Rimm EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001 157 495-503.
37. Hauner H, Petruschke T, Russ M, Rohrig K & Eckel J. Effects of tumour necrosis factor alpha (TNF α) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995 38 764-771.
38. Borst SE, Lee Y, Conover CF, Shek EW & Bagby GJ. Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle but not adipose tissue. American Journal of Physiology. Endocrinology and Metabolism 2004 287 E934-E938.
39. Wang Z, Lv J, Zhang R, Zhu Y, Zhu D, Sun Y, Zhu J & Han X. Co-culture with fat cells induces cellular insulin resistance in primary hepatocytes. Biochemical and Biophysical Research Communications 2006 345 976-983.
40. Palik E, Baranyi E, Melczer Z, Audikovszky M, Szocs A, Winkler G & Cseh K. Elevated serum acylated (biologically active) ghrelin and resistin levels associate with pregnancy-induced weight gain and insulin resistance. Diabetes Research and Clinical Practice 200 76 351-357.
41. Maruna P, Gurlich R, Frasko R & Rosicka M. Ghrelin and leptin elevation in postoperative intra-abdominal sepsis. European Surgical Research 2005 37 354-359.
42. Peracchi M, Bardella MT, Caprioli F, Massironi S, Conte D, Valenti L, Ronchi C, Beck-Peccoz P, Arosio M & Piodi L. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut 2006 55 432-433.
43. Hotamisligil GS, Shargill NS & Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 259 87-91.
44. Bemelmans MH, van Tits LJ & Buurman WA. Tumor necrosis factor: function, release and clearance. Critical Reviews in Immunology 1996 16 1-11.
45. Pennica D, Kohr WJ, Fendly BM, Shire SJ, Raab HE, Borchardt PE, Lewis M & Goeddel DV. Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation. Biochemistry 1992 31 1134-1141.
46. Raina N, Lamarre J, Liew CC, Lofti AH & Jeejeebhoy KN. Effect of nutrition on tumor necrosis factor receptors in weight-gaining and -losing rats. American Journal of Physiology 1999 277 E464-E473.
47. Ryan AS & Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004 27 1699-1705.
48. Bastard JP, Jardel C, Bruckert E, Vidal H & Hainque B. Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes, Obesity and Metabolism 2000 2 323-325.
49. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E & Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001 50 707-709.
50. Ridker PM, Buring JE, Cook NR & Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003 107 391-397.
51. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN & Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 1121-1127.
52. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL & Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999 99 237-242.
53. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR & Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000 321 199-204.
54. Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 327-334.
55. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ & Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002 51 1596-1600.